|
Tuesday, 6 June 2023, 20:00 HKT/SGT | |
| | | | Source: GeneTex | |
|
|
IRVINE, CA, June 6, 2023 - (ACN Newswire) - GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact: Allen Lee Phone: 949.553.1900 Email: allensl@genetex.com www.genetex.com
Contact Information Allen Lee Vice President - Business Development allensl@genetex.com (949)553-1900
Topic: Press release summary
Source: GeneTex
Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
New Horizons for SMEs in the Johor-Singapore SEZ
July 17, 2024 12:00 HKT/SGT
|
|
|
Save A Train Presents Another New and Unique Addition to its Expanding Global Rail Platform: Rail Forward!
July 17, 2024 10:00 HKT/SGT
|
|
|
The Laughing Cow Brings Innovation to Snacking with Delicious Cheez Dippers
July 17, 2024 10:00 HKT/SGT
|
|
|
Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship
Tuesday, July 16, 2024 10:26:00 PM
|
|
|
Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators
July 16, 2024 22:00 HKT/SGT
|
|
|
Lexaria Preparing For Strategic Growth
July 16, 2024 21:20 HKT/SGT
|
|
|
'Alamein Festival' Launches Exciting Second Edition for 2024
July 16, 2024 21:00 HKT/SGT
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
July 16, 2024 20:00 HKT/SGT
|
|
|
How Artificial Intelligence Can Help Give Your Business a Boost
July 16, 2024 19:30 HKT/SGT
|
|
|
U.S. Polo Assn. Proudly Partners with the 2024 Outsourcing Inc. Royal Charity Polo Cup
July 16, 2024 19:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|